Supplementary Materials for the First Quarter Financial Results for the Fiscal Year Ending March 2027 | Shionogi & Co.,Ltd. (4507) timely disclosure

Worth reading

64In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

635

¥100 million

Wording

Conditional

How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 20278 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥1,633 100 million+63.7%

Operating profit¥669 100 million+90.6%

Ordinary income¥737 100 million+59.2%

Net income¥977 100 million+148.3%

Selling, general and administrative expenses¥452 100 million

Operating profit margin

Rate41.0%

Results for the three months of the current quarterRevenue ¥163.3 billion, operating profit ¥66.9 billion, profit before tax for the quarter ¥73.7 billion, profit for the quarter ¥97.7 billion, profit for the quarter attributable to owners of the parent ¥97.7 billion, EBITDA ¥93.4 billion

Full-year earnings forecast

Revenue

¥7,000 100 million

Cost of sales

¥-1,200 100 million

Gross profit

¥5,800 100 million

Selling, general and administrative expenses

¥-1,816 100 million

Research and development costs

¥-1,550 100 million

Amortization of Intangible Assets Related to Products

¥-584 100 million

Other Income

¥350 100 million

Operating profit

¥2,200 100 million

Pretax profit

¥2,200 100 million

Profit attributable to owners of the parent

¥2,100 100 million

Capital expenditures

¥394 100 million

Depreciation and amortization

¥804 100 million

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。

Revenue23.3%

Cost of sales25.7%

Gross profit22.8%

Selling, general and administrative expenses24.9%

Research and development costs20.5%

Amortization of Intangible Assets Related to Products27.1%

Other Income77.6%

Operating profit30.4%

Profit before quarterly income taxes33.5%

Profit attributable to owners of the parent46.5%

Revenue by Business

Prescription Medicines in Japan18.8%

Overseas Subsidiaries/Exports24.1%

Contract Development and Manufacturing27.4%

Over-the-counter medicines15.4%

Royalty income25.8%

Capital expenditures6.4%

Depreciation and amortization26.0%

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Revenue

Prescription Medicines in Japan+¥19.4 billion

Overseas Subsidiaries/Exports+¥28.0 billion

Royalty income+¥16.2 billion

Selling, general and administrative expensesIncrease in sales-related expenses in the U.S. business and in connection with the consolidation of Torii Pharmaceutical

Research and development costsIncrease due to the pharmaceutical business of JT and the consolidation of Torii Pharmaceutical

Amortization of Intangible Assets Related to ProductsIncrease due to the pharmaceutical business of JT and the transfer of the edaravone business

Other IncomeIncrease in connection with ViiV becoming an equity-method affiliate

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Dollar

Average153

Pound

Average205

Euro

Average184

New initiatives

Transfer of the edaravone business
Changes in development stages (pediatric cefiderocol, pediatric ensitrelvir and post-exposure prophylaxis, Secutrelvir, and naldemedine)

Key KPIsA metric the company considers important as a management benchmark.

EBITDA

¥934 100 million

Year on year against the same period last year+¥52.8 billion

Basic earnings per share

¥114.81

Diluted Earnings per Share

¥114.78

ROE

5.6 %

ROA

2.8 %

Operating Margin on Revenue

41 %

Equity ratio attributable to owners of the parent

66.7 %

Number of employees

6,453 people

Segment results

Prescription Medicines in Japan

Sales¥33.5 billion

Year on year against the same period last year137.3%

Overseas Subsidiaries/Exports

Sales¥42.2 billion

Year on year against the same period last year196.6%

Contract Development and Manufacturing

Sales¥4 billion

Year on year against the same period last year-11.0%

Over-the-counter medicines

Sales¥2.9 billion

Year on year against the same period last year19.6%

Royalty income

Sales¥80.1 billion

Year on year against the same period last year25.3%

Other

Sales¥600 million

Year on year against the same period last year-4.4%

Number of employees

Number of Employees6,453 people

Capital expenditures

¥25 100 million

Payout ratio

28.9% (FY2025 actual); targets for total payout ratio and DOE: not disclosed

Contents of this document
Item	Details
Document type	Supplementary materials to the earnings report
Fiscal Period Covered	First quarter of the fiscal year ending March 2027
Net Sales	¥1,633 100 million (YoY +63.7%)
Operating profit	¥669 100 million (YoY +90.6%)
Ordinary income	¥737 100 million (YoY +59.2%)
Net income	¥977 100 million (YoY +148.3%)
Operating profit margin	Rate 41.0% / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses	¥452 100 million
Results for the three months of the current quarter	Revenue ¥163.3 billion, operating profit ¥66.9 billion, profit before tax for the quarter ¥73.7 billion, profit for the quarter ¥97.7 billion, profit for the quarter attributable to owners of the parent ¥97.7 billion, EBITDA ¥93.4 billion
Full-year earnings forecast	Revenue ¥7,000 100 million / Cost of sales ¥-1,200 100 million / Gross profit ¥5,800 100 million / Selling, general and administrative expenses ¥-1,816 100 million / Research and development costs ¥-1,550 100 million / Amortization of Intangible Assets Related to Products ¥-584 100 million / Other Income ¥350 100 million / Operating profit ¥2,200 100 million / Pretax profit ¥2,200 100 million / Profit attributable to owners of the parent ¥2,100 100 million / Capital expenditures ¥394 100 million / Depreciation and amortization ¥804 100 million
Progress against full-year forecast	Revenue 23.3% / Cost of sales 25.7% / Gross profit 22.8% / Selling, general and administrative expenses 24.9% / Research and development costs 20.5% / Amortization of Intangible Assets Related to Products 27.1% / Other Income 77.6% / Operating profit 30.4% / Profit before quarterly income taxes 33.5% / Profit attributable to owners of the parent 46.5% / Revenue by Business Prescription Medicines in Japan 18.8% / Overseas Subsidiaries/Exports 24.1% / Contract Development and Manufacturing 27.4% / Over-the-counter medicines 15.4% / Royalty income 25.8% / Capital expenditures 6.4% / Depreciation and amortization 26.0%
Segment results	Prescription Medicines in Japan Sales ¥33.5 billion / Year on year against the same period last year 137.3% / Overseas Subsidiaries/Exports Sales ¥42.2 billion / Year on year against the same period last year 196.6% / Contract Development and Manufacturing Sales ¥4 billion / Year on year against the same period last year -11.0% / Over-the-counter medicines Sales ¥2.9 billion / Year on year against the same period last year 19.6% / Royalty income Sales ¥80.1 billion / Year on year against the same period last year 25.3% / Other Sales ¥600 million / Year on year against the same period last year -4.4%
Breakdown of Factors Affecting the Change	Revenue Prescription Medicines in Japan +¥19.4 billion / Overseas Subsidiaries/Exports +¥28.0 billion / Royalty income +¥16.2 billion / Selling, general and administrative expenses Increase in sales-related expenses in the U.S. business and in connection with the consolidation of Torii Pharmaceutical / Research and development costs Increase due to the pharmaceutical business of JT and the consolidation of Torii Pharmaceutical / Amortization of Intangible Assets Related to Products Increase due to the pharmaceutical business of JT and the transfer of the edaravone business / Other Income Increase in connection with ViiV becoming an equity-method affiliate
Key KPIs	EBITDA ¥934 100 million / Basic earnings per share ¥114.81 / Diluted Earnings per Share ¥114.78 / ROE 5.6 % / ROA 2.8 % / Operating Margin on Revenue 41 % / Equity ratio attributable to owners of the parent 66.7 % / Number of employees 6,453 people
Number of employees	Number of Employees 6,453 people / Changes during the period and hiring plan Not disclosed
Assumptions Underlying the Business Outlook	Dollar Average 153 / Pound Average 205 / Euro Average 184
Payout ratio	28.9% (FY2025 actual); targets for total payout ratio and DOE: not disclosed
Capital expenditures	¥25 100 million
New initiatives	Transfer of the edaravone business, Changes in development stages (pediatric cefiderocol, pediatric ensitrelvir and post-exposure prophylaxis, Secutrelvir, and naldemedine)

Items this document does not state (12)

Gross Profit MarginSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased by ¥19.4 billion from domestic prescription pharmaceuticals, ¥28.0 billion from overseas subsidiaries and exports, and ¥16.2 billion from royalty income. Operating expenses increased due to the consolidation of Torii Pharmaceutical, the transfer of the edaravone business, the transfer of JT's pharmaceutical business, and sales-related expenses for the U.S. business. Other income increased in connection with ViiV becoming an equity-method affiliate.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.